)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Arcus Biosciences
Arcus Biosciences (RCUS) investor relations material
Arcus Biosciences Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Late-stage oncology programs center on casdatifan in clear-cell renal cell carcinoma (ccRCC) and quemliclustat in first-line metastatic pancreatic cancer; the immunology pipeline is expanding.
October ARC-20 data supported casdatifan activity across ccRCC treatment lines, with no unexpected safety signals at the data cutoff.
The portfolio spans multiple treatment lines and combines wholly owned programs with regional rights and partnerships.
Financial highlights
Q3 revenue was $9M vs. $26M YoY; license and development services revenue was $8M vs. $20M, and other collaboration revenue was $1M vs. $6M.
Q3 R&D expense was $117M vs. $141M YoY, G&A was $23M vs. $27M, and total operating expenses were $140M vs. $168M.
Q3 net loss was $128M vs. $135M, and diluted loss per share was $1.00 vs. $1.27.
Nine-month revenue was $67M vs. $214M; net loss was $347M vs. $247M.
September 30 cash, cash equivalents and marketable securities were $694M; October’s offering generated $288M gross proceeds and $270M net proceeds.
Outlook and guidance
Cash and investments plus October offering proceeds are expected to fund planned operations into 2029; expected FY 2026 GAAP revenue is $70M–$75M.
PEAK-1, the Phase 3 casdatifan plus cabozantinib study in 2L ccRCC, is fully enrolled; PEAK-20 is expected to initiate in Q4 2026.
PRISM-1 completed enrollment; its Phase 3 interim analysis in 1L metastatic pancreatic cancer is expected in Q4 2026.
2027 plans include more mature ARC-20 data and early data for casdatifan combinations with ivonescimab and tivozanib; PEAK-1 Phase 3 data and casdatifan plus tivozanib data are anticipated in 2028.
R&D expense is expected to remain relatively consistent near term as increased casdatifan and immunology investment offsets decreases in other programs.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Arcus Biosciences
- Casdatifan data and Phase 3 plans span RCC treatment lines.RCUS
Investor Day 2026 - Pivotal ARC-20 data and phase III trials aim to establish casdatifan as a market leader in RCC.RCUSMorgan Stanley 24th Annual Global Healthcare Conference
- Upcoming data for casdatifan may establish new benchmarks in kidney cancer treatment efficacy.RCUS12th Annual Cantor Fitzgerald Global Healthcare Conference
- Major October data update for casdatifan aims to boost confidence in pivotal renal cancer trials.RCUSCitigroup’s Biopharma Back to School Summit 2026
- Casdatifan and quemliclustat lead a robust pipeline with strong late-stage data and major market potential.RCUSCorporate presentation
- Casdatifan advanced in RCC, new partnerships secured, and $775M cash runway projected into 2028.RCUSQ2 2026
- Castatinopathy demonstrates superior efficacy in RCC trials, targeting major market growth.RCUSH.C. Wainwright 27th Annual Global Investment Conference
- Q1 2025 net loss was $112M on $28M revenue; cash reserves strong at $1B.RCUSQ1 2025
- Casdatifan outperforms belzutifan in ccRCC, with strong efficacy, safety, and major market potential.RCUSStatus Update
Next Arcus Biosciences earnings date
Jefferies Global Healthcare Conference16 Nov, 2026
Arcus Biosciences
Next Arcus Biosciences earnings date
Jefferies Global Healthcare Conference16 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Arcus Biosciences Inc (RCUS) is a clinical-stage biopharmaceutical company focused on the development of cancer immunotherapies. By leveraging underexploited biological opportunities, Arcus aims to create treatments that can significantly improve patient outcomes. The company's product pipeline features a range of candidates, including AB928, a dual antagonist for adenosine receptors A2aR and A2bR, in combination with an anti-PD-1 antibody (AB122) and chemotherapy for treating metastatic triple-negative breast cancer or ovarian cancer and advanced malignancies. The company is headquartered in Hayward, California, and its shares are listed on the NYSE.